Rapid Micro Biosystems (RPID) 2026 KeyBanc Capital Markets Healthcare Forum summary

Industry context and technology overview

• Microbial quality control is a critical, regulated step in pharmaceutical manufacturing to ensure product safety, especially for injectables, with current methods largely unchanged for a century and prone to human error and data integrity issues.

• The Growth Direct platform automates this process, offering faster, more reliable results and addressing regulatory demands for data integrity and automation.

• The business model leverages proprietary consumables and services, driving high recurring revenue.

Growth Direct Day and customer engagement

• Growth Direct Day, now held in Europe, North America, and Asia, saw record attendance with over 100 participants from multiple regions.

• The event focuses on peer coaching, best practices, and business case discussions, accelerating sales opportunities and fostering a community around the technology.

Financial guidance and growth drivers

• 2026 revenue guidance is $37M–$41M, based on 30–38 system placements, with a midpoint growth target of 16%.

• Key variables impacting guidance include customer capital environment, large multi-system orders, and the MilliporeSigma distribution commitment.

• The MilliporeSigma agreement is a five-year distribution deal with a meaningful annual commitment, influencing the upper and lower ends of guidance.